News roundup Wednesday, January 22

The latest from BioStock

» Xintela aims for new milestones in 2025
» Recruitment halfway through – Lipidor expects results in April
» Positive results for Xsprays XS003
» 304 million to take Gesynta Pharma through phase II
» Alzinova CEO: “Our clinical data was received with great enthusiasm at JPM”

Read the newsletter for v.3 here.

The latest news

entered into a joint venture with Kotler to develop China and other Asian markets. Read more. 

Stayble Therapeutics announces that the company's abstract on the effect of STA363 on disc volume has been accepted for presentation at the International Society for the Study of the Lumbar Spine (ISSLS) annual meeting. Read more.

AcuCort secures full subscription in rights issue through top guarantee. Read more.

Newbury Pharmaceuticals receives approval for generic Bosutinib. Read more.

Guard Therapeutics establishes scientific committee to strengthen Phase III development of RMC-035. Read more.

BiBBInstruments announces preliminary outcome of rights issue. Read more.

Integral welcomes new board members. Read more.

PolarCool extends contract with the Football Association of Wales. Read more.

Diagonal Bio publishes memorandum ahead of rights issue. Read more.

Glycorex Transplant has decided on a directed new issue of B shares of SEK 10 million. Read more.

Lytix Biopharma license partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference. Read more.

SyntheticMR appoints CFO Johanna Norén to acting CEO. Read more.

Johnson & Johnson announces that Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) shows a median survival of over one year compared to osimertinib. Read more.

Arjo launches the Symbliss bathing system. Read more.

Report

Alligator Bioscience  Flerie

Invitation

Coloplast

Communiqué

DanCann Pharma

This morning's price development